Meeting
2019 Genitourinary Cancers Symposium
Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.
Authors
Nicholas J. Vogelzang
Comprehensive Cancer Centers of Nevada, Las Vegas, NV
Nicholas J. Vogelzang , Philip W. Kantoff , Mark C. Scholz , Jeffrey L. Vacirca , Shaker R. Dakhil , Sanjay Goel , Matthew Harmon , Hong Tang , Bruce Brown , Andrew J. Armstrong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT00065442
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 174)
DOI
10.1200/JCO.2019.37.7_suppl.174
Abstract #
174
Poster Bd #
G17
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Real-world PROCEED registry data: Sipuleucel-T in elderly men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Andrew J. Armstrong
Poster
2016 Genitourinary Cancers Symposium
Analysis of the PROCEED registry by baseline prostate-specific antigen (PSA) quartiles: Preliminary analysis of real-world sipuleucel-T (sip-T) use.
First Author: Celestia S. Higano
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of 68Ga-PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide.
First Author: Amelia Altavilla
Poster
2022 ASCO Annual Meeting
Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.
First Author: Kambiz Rahbar